Loxo Oncology, Inc. (LOXO) Price Target Lowered to $108.00 at Citigroup Inc.

Loxo Oncology, Inc. (NASDAQ:LOXO) had its price target reduced by Citigroup Inc. from $112.00 to $108.00 in a research report report published on Thursday morning. They currently have a buy rating on the biopharmaceutical company’s stock.

LOXO has been the topic of several other research reports. BidaskClub raised Loxo Oncology from a sell rating to a hold rating in a research note on Saturday, August 12th. Zacks Investment Research raised Loxo Oncology from a hold rating to a buy rating and set a $82.00 price target for the company in a research note on Wednesday, August 9th. Stifel Nicolaus reissued a buy rating and issued a $94.00 price target (up previously from $71.00) on shares of Loxo Oncology in a research note on Thursday, August 10th. BTIG Research reissued a buy rating and issued a $75.00 price target on shares of Loxo Oncology in a research note on Thursday, August 3rd. Finally, Ifs Securities reissued an outperform rating on shares of Loxo Oncology in a research note on Tuesday, August 8th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Loxo Oncology presently has an average rating of Buy and a consensus target price of $90.57.

Loxo Oncology (LOXO) traded up $0.16 during trading hours on Thursday, reaching $75.07. The company’s stock had a trading volume of 336,424 shares, compared to its average volume of 370,798. Loxo Oncology has a 52 week low of $25.25 and a 52 week high of $95.92.

ILLEGAL ACTIVITY WARNING: “Loxo Oncology, Inc. (LOXO) Price Target Lowered to $108.00 at Citigroup Inc.” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.com-unik.info/2017/11/17/loxo-oncology-inc-loxo-price-target-lowered-to-108-00-at-citigroup-inc.html.

In related news, Director Lori Anne Kunkel sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $84.91, for a total value of $424,550.00. Following the completion of the sale, the director now directly owns 15,040 shares in the company, valued at approximately $1,277,046.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Joshua H. Bilenker sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 19th. The stock was sold at an average price of $89.02, for a total value of $1,335,300.00. Following the completion of the sale, the chief executive officer now owns 196,207 shares of the company’s stock, valued at $17,466,347.14. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 76,814 shares of company stock valued at $6,548,261. Corporate insiders own 44.40% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Quantbot Technologies LP acquired a new position in shares of Loxo Oncology during the third quarter worth approximately $122,000. Ameritas Investment Partners Inc. lifted its holdings in shares of Loxo Oncology by 31.3% during the second quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 419 shares during the last quarter. BNP Paribas Arbitrage SA lifted its holdings in shares of Loxo Oncology by 4,388.0% during the second quarter. BNP Paribas Arbitrage SA now owns 2,244 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 2,194 shares during the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Loxo Oncology during the third quarter worth approximately $212,000. Finally, SG Americas Securities LLC acquired a new position in shares of Loxo Oncology during the second quarter worth approximately $228,000. Institutional investors own 99.31% of the company’s stock.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Analyst Recommendations for Loxo Oncology (NASDAQ:LOXO)

What are top analysts saying about Loxo Oncology Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Loxo Oncology Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit